Other possible serious side effects include inflammation of the pancreas, low blood sugar, allergic reactions, kidney problems, gallbladder issues, stomach paralysis, thyroid tumors, or cancer.

Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...

CVS Health's new chief executive, David Joyner named former UnitedHealth Group executive Steve Nelson as head of Aetna, CVS's troubled insurance unit. A senior AstraZeneca executive is under detention ...

The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk's Wegovy sales exceed forecasts, boosting shares by 9%. U.S. demand remains high with expanded supply plans and ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its year-end outlook. Wall Street wasn't cheery about that.

On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 and nearly doubling the total for Lilly’s Zepbound.